Table 2.
Quantitative Analysis of P-gp Upregulation Using Simple Western Assaya
| glutamate
|
pilo (high dose)
|
pilo (fractionated dose)
|
CE
|
human
|
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ctrl | Glu | Ctrl | SE | Ctrl | SE | Ctrl | CE | Ctrl | EPI | |
| P-gp (ng) | 6.68 ± 0.17 | 10.6 ± 0.14 | 3.95 ± 0.04 | 5.54 ± 0.36 | 3.27 ± 0.03 | 5.00 ± 0.46 | 4.48 ± 0.63 | 6.27 ± 0.16 | 7.5 ± 0.2 | 10.5 ± 0.5 |
| ratio (treated/control) | 1.58 ± 0.04 | 1.40 ± 0.09 | 1.52 ± 0.44 | 1.40 ± 0.20 | 1.4 ± 0.22 | |||||
a
The table shows protein content (ng) per sample and the ratio of P-gp upregulation in all four models that were combined with capillary isolation: (1) ex vivo glutamate model (p < 0.00001), (2) high-dose SE model (p < 0.019), (3) fractionated SE model (p < 0.0002), and (4) chronic epilepsy model (p < 0.009). Data are mean ± SD (n = 3), two-tailed unpaired Student’s t-test was used to evaluate differences between controls and treated groups.